Analysts’ Viewpoint
Rise in prevalence of melasma, increase in awareness about the condition, and availability of effective & safe treatments are driving the global melasma drug treatment industry growth. Surge in awareness about the condition among healthcare professionals and people has led to rise in demand for effective and safe treatments for melasma, particularly among women who are most commonly affected by the condition. Furthermore, aging population and availability of advanced treatments is expected to propel global melasma drug treatment market size in the next few years.
Development of new topical treatments, such as hydroquinone and more advanced treatments including laser therapy and chemical peels, offers lucrative opportunities to market players. Manufacturers are focusing on natural and organic products for the treatment of melasma that contain ingredients such as vitamin C, arbutin, and licorice extract.
Melasma is a complex condition that can be caused by a range of factors, including hormonal changes, sun exposure, and genetics. Several types of melasma drug treatments are available, including topical treatments, such as hydroquinone, tretinoin, and corticosteroids, and more advanced treatments such as laser therapy and chemical peels.
Topical treatments are the most commonly used types of melasma drug treatment. These work by reducing the production of melanin, the pigment that causes dark patches on the skin.
There has been a trend toward the development of natural and organic products for the treatment of melasma in the past few years. The melasma drug treatment market demand is driven by factors such as rise in prevalence of melasma, aging population, and increase in demand for cosmetic treatments. However, the market is also subject to challenges such as regulatory hurdles and competition from alternative treatments.
Melasma affects an estimated 50 million people across the world, and its prevalence is increasing globally. The condition could have a significant impact on a person's quality of life, causing emotional distress and self-consciousness.
Rise in awareness about melasma among patients and healthcare providers is fueling demand for effective treatment options. This has led to increased research & development efforts by pharmaceutical companies to develop new and innovative treatments for the condition.
Surge in prevalence of melasma is also driven by changes in lifestyle, hormonal imbalances, and exposure to environmental factors such as ultraviolet (UV) radiation. As people spend more time outdoors and are exposed to higher levels of UV radiation, they are at increased risk of developing melasma. Additionally, hormonal changes associated with pregnancy, menopause, and the use of hormonal contraceptives could increase the risk of developing melasma.
In response to these trends, pharmaceutical companies are developing new drugs and treatment options that target the underlying causes of melasma. These include topical creams and gels, oral melasma medications, and injectable therapies that contain active ingredients such as hydroquinone, retinoids, corticosteroids, and azelaic acid. These drugs work by reducing hyperpigmentation and improving the appearance of melasma.
Advances in drug development are driving global melasma drug treatment market development. New and innovative treatment options are being developed that are both safe and effective. Pharmaceutical companies are investing in research & development to discover and develop new drugs that can specifically target the underlying causes of melasma.
One of the most significant advances in drug development for melasma is the development of novel compounds and delivery systems. There has been a growing interest in botanical extracts and natural compounds that have shown to have skin-lightening properties. These compounds, including kojic acid, arbutin, and licorice extract, are increasingly being used in creams and gels as the topical melasma treatment.
Development of advanced drug delivery systems is also driving the global melasma drug treatment market. These systems are designed to improve the penetration and efficacy of drugs by optimizing their pharmacokinetics and pharmacodynamics.
Some companies are developing nanoemulsion-based drug delivery systems that can improve the solubility and bioavailability of active compounds, leading to better treatment outcomes.
In terms of type of melasma, the mixed melasma segment accounted for the largest global melasma drug treatment market share of 70% in 2022. High prevalence of mixed melasma, driven by hormonal changes, sun exposure, and genetic factors, has led to significant demand for effective treatment options. Hence, pharmaceutical companies are investing in research & development to develop new and more effective treatments for this common condition.
Based on route of administration, the topical segment dominated the global melasma drug treatment market in 2022. Topical treatments are applied directly to the affected area of the skin, making them easy to use and non-invasive.
Patients can apply the treatment themselves, which eliminates the need for medical supervision and reduces healthcare costs. Convenience and ease of use make topical treatments a preferred option for many patients, particularly those with mild to moderate melasma.
Topical treatments are also generally well-tolerated by patients and have a low risk of side effects. This is because the active ingredients in topical treatments are delivered directly to the affected area of the skin, minimizing systemic exposure and reducing the risk of adverse events. This safety profile makes topical treatments an attractive option for patients who are concerned about the potential risks associated with other treatment options.
In terms of gender, the women segment held the largest global melisma drug treatment market share in 2022. This is ascribed to higher prevalence of melasma among women than men. Melasma is a common skin condition that affects up to 50 million people worldwide, with women being more likely to develop the condition than men.
Hormonal changes are a significant factor in the development of melasma, and women are more susceptible to hormonal changes than men. The condition is more common in women who are pregnant or taking hormonal contraceptives, which can cause an increase in the production of melanin, the pigment that causes hyperpigmentation.
Higher prevalence of melasma in women, driven by hormonal changes, sun exposure, and genetic factors, has led to larger demand for effective treatment options among women.
Based on drug agent, the hydroquinone segment dominated the global melasma drug treatment market in 2022. Hydroquinone is the most commonly used active ingredient in the treatment of melasma.
It is highly effective in reducing hyperpigmentation and improving the overall appearance of the skin. It works by inhibiting the production of melanin, the pigment that causes hyperpigmentation. It does this by blocking the enzyme responsible for the conversion of tyrosine to melanin. This results in reduction in the amount of melanin produced, which in turn reduces hyperpigmentation.
Hydroquinone has been used for the treatment of melasma for over 50 years and is considered the gold standard treatment. It is available in different strengths, ranging from 2% to 4%, and can be used alone or in combination with other active ingredients, such as retinoids or corticosteroids.
Hydroquinone is effective in treating all types of melasma, including epidermal, dermal, and mixed. It is particularly effective in treating epidermal melasma, which is the most common type of melasma.
In terms of distribution channel, the offline segment accounted for the largest market share in 2022. Offline channels, such as brick-and-mortar pharmacies and drugstores, are preferred by many patients for purchasing medication.
Patients may feel more comfortable speaking with a pharmacist or healthcare professional in person to obtain information about their condition and treatment options. This interaction can also provide an opportunity for patients to ask questions and receive personalized advice about their treatment.
Offline channels also offer greater convenience and ease of access for many patients. Patients can easily walk into a pharmacy or drugstore and purchase medication without having to wait for shipping or delivery. This is particularly important for patients who require immediate treatment for their condition.
As per melasma drug treatment market trends, Asia Pacific accounted for the major market share in 2022. This is ascribed to high prevalence of melasma and large population. The region also has a sizeable and growing middle class, which is driving demand for cosmetic products and treatments.
Melasma is a cosmetic concern, and several people seek treatment to improve the appearance of their skin. Consequently, there is a growing market for melasma treatments in Asia Pacific, which is expected to augment the market in the next few years. Moreover, the region has a large and diverse population, which is driving innovation in the development of new melasma treatments.
Melasma is a common skin condition in North America, affecting up to 10% of the population. High prevalence of melasma has driven demand for effective treatment options, resulting in a large and growing market for melasma drug treatments.
The aging population in Europe is fueling demand for cosmetic treatments, including those for melasma. As people age, they could develop age spots and other skin discolorations, which can be a cosmetic concern. This has led to a growing market for melasma treatment in Europe, particularly among older adults.
The global melasma drug treatment market is fragmented, with the presence of large number of players. Companies are investing significantly in R&D to develop more effective treatments for melisma. AbbVie, Inc., Galderma, Obagi Cosmeceuticals LLC, Valeant Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Abbott, La Pristine, and MESOESTETIC are the prominent players in the market.
Each of these players has been profiled in the melasma drug treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 2.6 Bn |
|
Forecast Value in 2031 |
More than US$ 5.2 Bn |
|
Growth Rate (CAGR) |
8.3% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
It was valued at US$ 2.6 Bn in 2022
It is projected to reach more than US$ 5.2 Bn by 2031
It is anticipated to expand at a CAGR 8.3% from 2023 to 2031
Asia Pacific is expected to account for leading share from 2022 to 2031
AbbVie, Inc., Galderma, Obagi Cosmeceuticals LLC, Valeant Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Abbott, La Pristine, and MESOESTETIC.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Melasma Drug Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Melasma Drug Treatment Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. Disease Epidemiology
5.3. Regulatory Scenario
5.4. Pipeline Analysis
5.5. Covid-19 Impact Analysis
6. Global Melasma Drug Treatment Market Analysis and Forecast, by Type of Melasma
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Melasma, 2017-2031
6.3.1. Epidermal Melasma
6.3.2. Dermal Melasma
6.3.3. Mixed Melasma
6.4. Market Attractiveness Analysis, by Type of Melasma
7. Global Melasma Drug Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Topical
7.3.2. Oral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Melasma Drug Treatment Market Analysis and Forecast, by Gender
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Gender, 2017-2031
8.3.1. Men
8.3.2. Women
8.4. Market Attractiveness Analysis, by Gender
9. Global Melasma Drug Treatment Market Analysis and Forecast, by Drug Agent
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Drug Agent, 2017-2031
9.3.1. Hydroquinone
9.3.2. Topical Retinoid
9.3.3. Topical Steroid
9.3.4. Triple Combination Cream
9.3.5. Others
9.4. Market Attractiveness Analysis, by Drug Agent
10. Global Melasma Drug Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Offline
10.3.2. Online
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Melasma Drug Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Melasma Drug Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Melasma, 2017-2031
12.2.1. Epidermal Melasma
12.2.2. Dermal Melasma
12.2.3. Mixed Melasma
12.3. Market Value Forecast, by Route of Administration, 2017-2031
12.3.1. Topical
12.3.2. Oral
12.4. Market Value Forecast, by Gender, 2017-2031
12.4.1. Men
12.4.2. Women
12.5. Market Value Forecast, by Drug Agent, 2017-2031
12.5.1. Hydroquinone
12.5.2. Topical Retinoid
12.5.3. Topical Steroid
12.5.4. Triple Combination Cream
12.5.5. Others
12.6. Market Value Forecast, by Distribution Channel, 2017-2031
12.6.1. Offline
12.6.2. Online
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Type of Melasma
12.8.2. By Route of Administration
12.8.3. By Gender
12.8.4. By Drug Agent
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Melasma Drug Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Melasma, 2017-2031
13.2.1. Epidermal Melasma
13.2.2. Dermal Melasma
13.2.3. Mixed Melasma
13.3. Market Value Forecast, by Route of Administration, 2017-2031
13.3.1. Topical
13.3.2. Oral
13.4. Market Value Forecast, by Gender, 2017-2031
13.4.1. Men
13.4.2. Women
13.5. Market Value Forecast, by Drug Agent, 2017-2031
13.5.1. Hydroquinone
13.5.2. Topical Retinoid
13.5.3. Topical Steroid
13.5.4. Triple Combination Cream
13.5.5. Others
13.6. Market Value Forecast, by Distribution Channel, 2017-2031
13.6.1. Offline
13.6.2. Online
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. U.K.
13.7.2. Germany
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Type of Melasma
13.8.2. By Route of Administration
13.8.3. By Gender
13.8.4. By Drug Agent
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Melasma Drug Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Melasma, 2017-2031
14.2.1. Epidermal Melasma
14.2.2. Dermal Melasma
14.2.3. Mixed Melasma
14.3. Market Value Forecast, by Route of Administration, 2017-2031
14.3.1. Topical
14.3.2. Oral
14.4. Market Value Forecast, by Gender, 2017-2031
14.4.1. Men
14.4.2. Women
14.5. Market Value Forecast, by Drug Agent, 2017-2031
14.5.1. Hydroquinone
14.5.2. Topical Retinoid
14.5.3. Topical Steroid
14.5.4. Triple Combination Cream
14.5.5. Others
14.6. Market Value Forecast, by Distribution Channel, 2017-2031
14.6.1. Offline
14.6.2. Online
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Type of Melasma
14.8.2. By Route of Administration
14.8.3. By Gender
14.8.4. By Drug Agent
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Melasma Drug Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Melasma, 2017-2031
15.2.1. Epidermal Melasma
15.2.2. Dermal Melasma
15.2.3. Mixed Melasma
15.3. Market Value Forecast, by Route of Administration, 2017-2031
15.3.1. Topical
15.3.2. Oral
15.4. Market Value Forecast, by Gender, 2017-2031
15.4.1. Men
15.4.2. Women
15.5. Market Value Forecast, by Drug Agent, 2017-2031
15.5.1. Hydroquinone
15.5.2. Topical Retinoid
15.5.3. Topical Steroid
15.5.4. Triple Combination Cream
15.5.5. Others
15.6. Market Value Forecast, by Distribution Channel, 2017-2031
15.6.1. Offline
15.6.2. Online
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Type of Melasma
15.8.2. By Route of Administration
15.8.3. By Gender
15.8.4. By Drug Agent
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Melasma Drug Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Type of Melasma, 2017-2031
16.2.1. Epidermal Melasma
16.2.2. Dermal Melasma
16.2.3. Mixed Melasma
16.3. Market Value Forecast, by Route of Administration, 2017-2031
16.3.1. Topical
16.3.2. Oral
16.4. Market Value Forecast, by Gender, 2017-2031
16.4.1. Men
16.4.2. Women
16.5. Market Value Forecast, by Drug Agent, 2017-2031
16.5.1. Hydroquinone
16.5.2. Topical Retinoid
16.5.3. Topical Steroid
16.5.4. Triple Combination Cream
16.5.5. Others
16.6. Market Value Forecast, by Distribution Channel, 2017-2031
16.6.1. Offline
16.6.2. Online
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Type of Melasma
16.8.2. By Route of Administration
16.8.3. By Gender
16.8.4. By Drug Agent
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. AbbVie Inc.
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. GALDERMA
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Obagi Cosmeceuticals LLC.
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Valeant Pharmaceuticals
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. GLENMARK PHARMACEUTICALS LTD
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Abbott
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. La Pristine
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. MESOESTETIC
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
List of Tables
Table 01: Global Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 02: Global Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 03: Global Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 04: Global Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 05: Global Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06: Global Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07: North America Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 08: North America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 09: North America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10: North America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 11: North America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 12: North America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Europe Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Europe Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 15: Europe Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16: Europe Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 17: Europe Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 18: Europe Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 19: Asia Pacific Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 20: Asia Pacific Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 21: Asia Pacific Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 22: Asia Pacific Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 23: Asia Pacific Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 24: Asia Pacific Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 25: Latin America Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Latin America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 27: Latin America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 28: Latin America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 29: Latin America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 30: Latin America Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 31: Middle East and Africa Melasma Drug Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 32: Middle East and Africa Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Type of Melasma, 2017-2031
Table 33: Middle East and Africa Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 34: Middle East and Africa Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Drug Agent, 2017-2031
Table 35: Middle East and Africa Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2031
Table 36: Middle East and Africa Melasma Drug Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Melasma Drug Treatment Market Value Share, by Type of Melasma, 2022
Figure 03: Global Melasma Drug Treatment Market Value Share, by Route of Administration 2022
Figure 04: Global Melasma Drug Treatment Market Value Share, by Drug Agent, 2022
Figure 05: Global Melasma Drug Treatment Market Value Share, by Route of Administration, 2022
Figure 06: Global Melasma Drug Treatment Market Value Share, by Distribution Channel, 2022
Figure 07: Global Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 08: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Epidermal Melasma, 2017-2031
Figure 09: Global Melasma Drug Treatment Market Value Share Analysis, by Dermal Melasma, 2022 and 2031
Figure 10: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Mixed Plasma, 2017-2031
Figure 11: Global Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 12: Global Melasma Drug Treatment Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 13: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Topical, 2017-2031
Figure 14: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Oral 2017-2031
Figure 15: Global Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration 2023-2031
Figure 16: Global Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 17: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Hydroquinone, 2017-2031
Figure 18: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Topical Retinoid, 2017-2031
Figure 19: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Topical Steroid, 2017-2031
Figure 20: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Triple Combination Cream, 2017-2031
Figure 21: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Others, 2017-2031
Figure 22: Global Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 23: Global Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 24: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Men, 2017-2031
Figure 25: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Women, 2017-2031
Figure 26: Global Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 27: Global Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 28: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Offline, 2017-2031
Figure 29: Global Melasma Drug Treatment Market Revenue (US$ Mn), by Online, 2017-2031
Figure 30: Global Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 31: Global Melasma Drug Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 32: Global Melasma Drug Treatment Market Attractiveness Analysis, by Region, 2023-2031
Figure 33: North America Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 34: North America Melasma Drug Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 35: North America Melasma Drug Treatment Market Attractiveness Analysis, by Country, 2023-2031
Figure 36: North America Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 37: North America Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 38: North America Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 39: North America Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 40: North America Melasma Drug Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: North America Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 42: North America Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 43: North America Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 44: North America Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 45: North America Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 46: Europe Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 47: Europe Melasma Drug Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 49: Europe Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 50: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 51: Europe Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 52: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 53: Europe Melasma Drug Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 54: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 55: Europe Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 56: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 57: Europe Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 58: Europe Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 59: Asia Pacific Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 60: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 61: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 62: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 63: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 64: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 65: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 66: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 67: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 68: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 69: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 70: Asia Pacific Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 71: Asia Pacific Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 72: Latin America Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 73: Latin America Melasma Drug Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 74: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 75: Latin America Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 76: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 77: Latin America Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 78: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 79: Latin America Melasma Drug Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 80: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 81: Latin America Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 82: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 83: Latin America Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 84: Latin America Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 85: Middle East and Africa Melasma Drug Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 86: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 87: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 88: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Type of Melasma, 2022 and 2031
Figure 89: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Type of Melasma, 2023-2031
Figure 90: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Drug Agent, 2022 and 2031
Figure 91: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Drug Agent, 2023-2031
Figure 92: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 93: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 94: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Gender, 2022 and 2031
Figure 95: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Gender, 2023-2031
Figure 96: Middle East and Africa Melasma Drug Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 97: Middle East and Africa Melasma Drug Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 98: Company Share Analysis
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Melasma Drug Treatment Market
*86 figures and 60 tables includes